Why the study?
Controversy persists regarding whether patients with HFrEF in sinus rhythm can benefit from anticoagulation therapy.
Does anticoagulation therapy prevent recurrent thromboembolism and resolve intracardiac thrombus in a patient with HFrEF in sinus rhythm?
Case Report (n=1)
No
Does anticoagulation therapy prevent recurrent thromboembolism and resolve intracardiac thrombus in a patient with HFrEF in sinus rhythm?
This case highlights that patients with severe HFrEF in sinus rhythm and high-risk features may benefit from anticoagulation to prevent recurrent thromboembolic events.
Answers are grounded in this paper and cite their sources.
May support anticoagulation for thrombus in select HFrEF sinus-rhythm cases; hypothesis-generating and should not change practice.
Severe left ventricular dysfunction and ventricular wall motion abnormalities predispose individuals to thrombosis and thromboembolism. Thromboembolism is one of the main causes of increased mortality in patients with heart failure and reduced ejection fraction (HFrEF). However, regarding thromboembolism due to HFrEF in sinus rhythm, most cases to date have reported ischemic strokes, and repeated embolization of peripheral arteries has been reported not uncommon. Herein, we report the case of a 48-year-old man with a definite diagnosis of sinus rhythm HFrEF and recurrent peripheral arterial embolization within a short period. The condition is caused by severe left ventricular systolic dysfunction and abnormal left ventricular wall motion, resulting in blood stasis and abnormal blood composition, with or without left ventricular thrombosis, and can lead to thromboembolism. Current guidelines state that patients with heart failure and clear indication(s) for anticoagulation (e.g., atrial fibrillation, heart valve replacement) should be administered appropriate anticoagulation therapy. However, controversy persists regarding whether patients with HFrEF in sinus rhythm can benefit from anticoagulation therapy. This case highlights the utility and necessity of anticoagulation for the prevention of intracardiac thrombosis and the treatment of peripheral arterial embolism in patients with HFrEF in sinus rhythm.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2024) conducted a case report in Heart failure with reduced ejection fraction (HFrEF) in sinus rhythm (n=1). Anticoagulation (enoxaparin sodium followed by rivaroxaban) was evaluated on Resolution of intracardiac thrombus and prevention of new peripheral arterial embolization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: